rs157582 — TOMM40 TOMM40 memory variant

Intronic variant in TOMM40 (translocase of outer mitochondrial membrane 40) associated with aging-related verbal memory decline, accelerated hippocampal atrophy, and Alzheimer's disease risk, with effects partially independent of APOE

See your personal result for TOMM40

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

TOMM40 — The Mitochondrial Gateway to Memory Aging

Every protein your neurons need to maintain their mitochondria must be physically imported across the outer mitochondrial membrane. The protein that guards this gateway is TOM40, encoded by TOMM4011 TOMM40
Translocase of Outer Mitochondrial Membrane 40; one of the core components of the TOM complex, the main protein-import channel for the outer mitochondrial membrane. When TOMM40 function is compromised in neurons, mitochondrial biogenesis slows, ATP production falls, and the cellular stress that precedes neurodegeneration begins to accumulate. rs157582 sits in an intron of this gene on chromosome 19 — in the same genomic neighborhood as the better-known APOE variants — and is associated in multiple large population studies with accelerated memory decline and faster hippocampal shrinkage in aging.

The Mechanism

rs157582 is a non-coding intronic variant; it does not directly change the TOM40 protein sequence. Its effect is regulatory: the variant likely influences TOMM40 transcription levels, mRNA splicing, or local gene regulation within the densely packed APOE/TOMM40/APOC1 locus22 APOE/TOMM40/APOC1 locus
These three genes on chromosome 19q13.32 are in partial linkage disequilibrium; rs157582 in TOMM40 is physically between APOE and TOMM40 and multiple variants in this region are in LD with APOE ε4, though rs157582 has documented effects independent of APOE ε4 genotype.

The mechanistic link between TOMM40 variation and neurodegeneration involves two converging pathways. First, Alu retrotransposon insertions in TOMM40 introns33 Alu retrotransposon insertions in TOMM40 introns
Alu elements are primate-specific repetitive DNA sequences; at least one Alzheimer's disease-associated TOMM40 variant originated from an Alu insertion event per Larsen et al. 2017 can disrupt mRNA processing via aberrant splicing and A-to-I RNA editing, reducing functional TOM40 protein levels in neurons. Reduced TOM40 channel activity impairs mitochondrial protein import, lowering the supply of nuclear-encoded subunits needed for oxidative phosphorylation complexes. In neurons — which are uniquely dependent on mitochondria given their high energy demands and inability to rely on glycolysis — even partial TOM40 insufficiency accelerates mitochondrial dysfunction with age.

Second, dysfunctional TOMM40 activates neuroinflammatory cascades. TOMM40 loss-of-function experiments in microglial cells demonstrate NF-κB pathway activation and NLRP3 inflammasome assembly44 NF-κB pathway activation and NLRP3 inflammasome assembly
The NLRP3 inflammasome is a multiprotein complex that cleaves pro-IL-1β into its active form; its chronic activation in microglia is a hallmark of late-stage Alzheimer's disease pathology, with downstream secretion of IL-1β, IL-6, and TNF-α — pro-inflammatory cytokines that damage synapses and accelerate amyloid-beta and tau accumulation.

The Evidence

The largest genetic epidemiology evidence comes from a GWAS of aging-related verbal memory55 GWAS of aging-related verbal memory
Combined analysis of the Health and Retirement Study (HRS; N=7,486 genotyped) and English Longitudinal Study of Ageing (ELSA; N=6,898), measuring longitudinal immediate and delayed recall performance across multiple waves. rs157582 reached genome-wide significance for both immediate recall change after age 60 (meta-analysis p=8.3×10⁻¹⁰) and delayed recall level (p=7.0×10⁻⁹). Critically, conditional analyses demonstrated that the signal on immediate recall change was driven by TOMM40, not APOE — providing the strongest evidence to date that rs157582 influences memory aging through a partially independent mechanism.

Brain imaging corroborates this. In 602 non-demented elders from the ADNI cohort66 602 non-demented elders from the ADNI cohort
Alzheimer's Disease Neuroimaging Initiative; participants were non-Hispanic Caucasian adults without dementia at enrollment, followed longitudinally for hippocampal volume changes by MRI, the T allele of rs157582 was associated with faster hippocampal atrophy rate in a dose-dependent manner (p=1.23×10⁻⁸, genome-wide significant). T allele carriers showed lower Mini-Mental State Examination scores and higher Alzheimer's Disease Assessment Scale cognitive subscale scores, linking the genetic signal directly to measurable brain and cognitive outcomes even before dementia onset.

rs157582 also reaches genome-wide significance in GWAS for Alzheimer's disease itself (OR≈2.73 overall; OR≈2.83 in males, OR≈2.62 in females per Nazarian et al. 2019, PMID 30636644), and for CSF biomarkers of AD pathology including reduced Aβ1-42 (p=1×10⁻²³) and altered tau-to-Aβ ratios — the cerebrospinal fluid fingerprint of amyloid accumulation and tau hyperphosphorylation that precedes clinical dementia by 10–15 years.

Practical Actions

For T allele carriers, the actionable focus is on interventions that specifically support mitochondrial efficiency and limit neuroinflammatory burden. The critical distinction from APOE-focused guidance is timing: because the TOMM40 effect is strongest on rate of change in memory during normal aging (not just dementia risk), interventions aimed at preserving mitochondrial health are relevant decades before any cognitive symptoms emerge.

Coenzyme Q10 (ubiquinol form) directly supports mitochondrial electron transport chain efficiency. Creatine monohydrate supplements the phosphocreatine system that neurons use to buffer ATP supply during periods of high demand. DHA (the omega-3 found predominantly in brain tissue) maintains mitochondrial membrane fluidity, directly affecting the TOM complex's functional environment. These are not generic brain-health supplements — they target the specific mitochondrial import and energy production pathway that TOMM40 variation affects.

Cognitive baseline testing provides a concrete neurological anchor: by documenting your memory performance in your 40s or 50s (using validated tools like the MoCA, or a comprehensive neuropsychological battery), you create a personalized reference point that makes meaningful future change detectable much earlier than population-average norms allow.

Interactions

rs157582 sits within the APOE/TOMM40/APOC1 locus on chromosome 19, meaning it is in partial linkage disequilibrium with APOE ε4 (rs429358 T allele) and APOE ε2 (rs7412 T allele). However, the GWAS evidence distinguishes the signals: APOE drives delayed recall level, while TOMM40 rs157582 drives the rate of immediate recall change after age 60. Individuals carrying both rs157582 T and APOE ε4 face additive neurodegeneration risk from two partially independent biological pathways — amyloid clearance (APOE) and mitochondrial protein import efficiency (TOMM40). rs2075650, another TOMM40 intron variant, shows similar associations with cognitive aging but some fine-mapping studies suggest its signal is attributable to APOE ε4 LD rather than independent TOMM40 effect. rs10524523, the TOMM40 intron 6 poly-T variable-length polymorphism, has been studied specifically for Alzheimer's age-of-onset prediction and represents a separate functional variant in the same gene.

Genotype Interpretations

What each possible genotype means for this variant.

CC Standard Memory Aging Normal

Common genotype — typical age-related memory trajectory

You carry two copies of the C (reference) allele at rs157582 in TOMM40. About 62% of people of European descent share this genotype. This is the most common variant and is not associated with accelerated hippocampal atrophy or faster age-related verbal memory decline in population studies. Your TOMM40 gene expression is not specifically altered by this variant, and the neuroinflammatory and mitochondrial import effects associated with the T allele do not apply to you based on this SNP alone.

CT Accelerated Memory Risk Intermediate

One T allele — moderately elevated risk for age-related memory decline and hippocampal atrophy

As a CT heterozygote, you have one copy of the T allele that is associated with altered TOMM40 expression. The proposed mechanism involves disruption of mitochondrial protein import efficiency in neurons — TOM40 is the main channel through which nuclear-encoded mitochondrial proteins enter the organelle, and partial reduction in its function gradually impairs oxidative phosphorylation in high-energy-demand neurons. The inflammatory arm involves microglial NLRP3 inflammasome activation downstream of TOMM40 dysfunction, which elevates IL-1β, IL-6, and TNF-α — cytokines that damage synaptic density and accelerate amyloid and tau pathology.

The key practical insight is timing: because this variant's strongest documented effect is on the rate of memory change during normal aging (immediate recall change in the 60s), protective interventions targeting mitochondrial efficiency are most valuable when started in midlife, before functional decline begins. CSF biomarker evidence shows rs157582 T allele carriers have altered Aβ1-42 and tau ratios — the preclinical AD fingerprint — suggesting the biological process begins one to two decades before any clinical symptoms.

TT Elevated Memory Aging Risk High Risk

Two T alleles — highest TOMM40-conferred risk for accelerated memory decline and hippocampal atrophy

As a TT homozygote, both alleles carry the T variant associated with altered TOMM40 function. The dose-response relationship observed in hippocampal atrophy studies (CT carriers > CC, TT carriers > CT) suggests a gene-additive effect on mitochondrial protein import capacity in neurons. With two copies, the cumulative reduction in TOM40 channel function — compounded across decades of aging — is expected to be greater than in heterozygotes.

The neuroinflammatory consequence is also dose-dependent: TOMM40 dysfunction drives microglial NLRP3 inflammasome activation, elevating IL-1β, IL-6, and TNF-α. Chronic low-level neuroinflammation accelerates both amyloid plaque deposition and tau neurofibrillary tangle formation, accelerating the amyloid cascade. CSF biomarker GWAS data show rs157582 T allele is associated with reduced Aβ1-42 (p=2×10⁻¹⁵) and altered tau/Aβ ratios (p=3×10⁻²⁰–2×10⁻¹⁶), confirming that the molecular precursors of AD pathology are altered.

Practical implication: mitochondrial support interventions should begin in midlife (40s–50s), before hippocampal atrophy accumulates to a clinically detectable level. Neurological baseline documentation is particularly important for TT carriers because the rate of change is the key signal — and rate requires two time points separated by years.